Deals Of The Week: Abbott/Reata, Bristol-Myers Squibb/Simcere, Intarcia/Quintiles
Abbott sends another financial record tumbling as it pays an all-time high $400 million upfront for preclinical AIM compounds from Reata.
You may also be interested in...
Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs
Adding on to the two companies’ collaboration around chronic kidney disease candidate bardoxolone, Abbott will pay a record upfront for preclinical assets to co-develop and co-commercialize Reata’s antioxidant inflammation modulators in a variety of disease areas.
Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011
The two companies will co-develop and co-commercialize PCI-32765, which is being investigated in multiple types of hematological cancer.
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development